|
| 36926453 | Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy: and Evaluation on Reduction of the Cardiotoxicity Side Effect of Doxorubicin. | | 2023 |
| 36401732 | The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HRâ¿¿+â¿¿/HER2â¿¿-) advanced/metastatic breast cancer. | Breast Cancer Res Treat | 2023 |
| 37141550 | A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. | JCO Precis Oncol | 2023 |
| 37141549 | Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. | JCO Precis Oncol | 2023 |
| 37265453 | Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 37070653 | Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. | Future Oncol | 2023 |
| 36693175 | Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 36609389 | A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). | | 2023 |
| 34996889 | Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. | Nat Commun | 2022 |
| 35653124 | Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). | Clin Cancer Res | 2022 |
| 35879309 | KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data. | Nature Communications | 2022 |
| 36332363 | Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. | EBioMedicine | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 34864772 | Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs: An Observational Study of US Women (Ages 18-64 Years). | Journal of Clinical Psychopharmacology | 2022 |
| 35314693 | A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. | npj Breast Cancer | 2022 |
| 35044810 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 34565686 | A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. | Clinical Breast Cancer | 2022 |
| 34480623 | Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). | Support Care Cancer | 2021 |
| 33970392 | Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography. | Breast Cancer Research and Treatment | 2021 |
| 33753748 | Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. | NPJ Breast Cancer | 2021 |
| 34016993 | Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. | NPJ Breast Cancer | 2021 |
| 34173924 | Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 33531464 | Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. | Nature Communications | 2021 |
| 33997789 | CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. | Nat Cancer | 2021 |
| 33613616 | RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. | Front Genet | 2021 |
| 33989287 | A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patients. | PLoS One | 2021 |
| 33722897 | Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR<sup>+</sup>/HER2<sup>-</sup> Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). | Clin Cancer Res | 2021 |
| 33983438 | Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer. | JAMA Oncol | 2021 |
| 33981951 | Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). | JNCI Cancer Spectr | 2021 |
| 33556062 | A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment. | PLoS ONE | 2021 |
| 33761455 | Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. | J Natl Compr Canc Netw | 2021 |
| 33596420 | Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1. | Cell Reports | 2021 |
| 34310349 | Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors. | American Journal of Clinical Oncology: Cancer Clinical Trials | 2021 |
| 33201358 | Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. | Breast Cancer Research and Treatment | 2021 |
| 33148674 | Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i>-Mutant Cancers. | Clin Cancer Res | 2021 |
| 33190190 | Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. | Advances in Therapy | 2021 |
| 33347020 | Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. | Journal of Clinical Psychopharmacology | 2021 |
| 33219484 | Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). | Breast Cancer Res Treat | 2021 |
| 32500206 | Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). | Support Care Cancer | 2021 |
| 32770247 | Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. | J Natl Cancer Inst | 2021 |
| 34551967 | Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets. | Cancer Immunology Research | 2021 |
| 34383300 | Intermittent fasting in the prevention and treatment of cancer. | Ca-A Cancer Journal for Clinicians | 2021 |
| 34551235 | Breast Cancer, <i>HER2</i> Mutations, and Overcoming Drug Resistance. | N Engl J Med | 2021 |
| 34712959 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. | Nat Cancer | 2021 |
| 34429404 | Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. | Nat Commun | 2021 |
| 33371187 | Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. | Cancers (Basel) | 2020 |
| 32135512 | Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy. | Journal of the National Comprehensive Cancer Network : JNCCN | 2020 |
| 32415339 | Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor? | Current Oncology Reports | 2020 |
| 30787127 | Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. | J Natl Compr Canc Netw | 2019 |
| 31835495 | Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. | Cancers | 2019 |